Bavarian Nordic A/S (OTCMKTS:BVNRY) Sees Large Growth in Short Interest

Bavarian Nordic A/S (OTCMKTS:BVNRY) was the target of a large growth in short interest in the month of April. As of April 15th, there was short interest totalling 800 shares, a growth of 700.0% from the March 31st total of 100 shares. Based on an average daily trading volume, of 12,900 shares, the days-to-cover ratio is currently 0.1 days.

Bavarian Nordic A/S Price Performance

Shares of Bavarian Nordic A/S stock traded down $0.23 during midday trading on Thursday, hitting $6.92. 4,115 shares of the company were exchanged, compared to its average volume of 5,781. The firm has a 50 day simple moving average of $7.61 and a 200-day simple moving average of $7.59. Bavarian Nordic A/S has a 52 week low of $5.95 and a 52 week high of $10.65. The firm has a market cap of $1.62 billion, a P/E ratio of 7.53 and a beta of 1.50.

Bavarian Nordic A/S (OTCMKTS:BVNRY) last issued its quarterly earnings data on Wednesday, March 6th. The company reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.12. Bavarian Nordic A/S had a return on equity of 0.07% and a net margin of 20.80%. The firm had revenue of $353.27 million during the quarter, compared to the consensus estimate of $340.71 million. Equities research analysts expect that Bavarian Nordic A/S will post 0.52 earnings per share for the current year.

Bavarian Nordic A/S Company Profile

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name.